Marius C. Hoener
Marius C. Hoener
Ph.D., Distinguished Scientist, Head of Exploratory Biology, Drug Discovery Project Team Leader
Verified email at
Cited by
Cited by
Pharmacological characterization of designer cathinones in vitro
LD Simmler, TA Buser, M Donzelli, Y Schramm, LH Dieu, J Huwyler, ...
British journal of pharmacology 168 (2), 458-470, 2013
A renaissance in trace amines inspired by a novel GPCR family
L Lindemann, MC Hoener
Trends in pharmacological sciences 26 (5), 274-281, 2005
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity
FG Revel, JL Moreau, RR Gainetdinov, A Bradaia, TD Sotnikova, R Mory, ...
Proceedings of the national academy of sciences 108 (20), 8485-8490, 2011
Trace amine-associated receptor 1 modulates dopaminergic activity
L Lindemann, CA Meyer, K Jeanneau, A Bradaia, L Ozmen, ...
Journal of Pharmacology and Experimental Therapeutics 324 (3), 948-956, 2008
Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors
L Lindemann, M Ebeling, NA Kratochwil, JR Bunzow, DK Grandy, ...
Genomics 85 (3), 372-385, 2005
Trace amines and their receptors
RR Gainetdinov, MC Hoener, MD Berry
Pharmacological reviews 70 (3), 549-620, 2018
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
A Rickli, OD Moning, MC Hoener, ME Liechti
European Neuropsychopharmacology 26 (8), 1327-1337, 2016
Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin, and DJ-1 in Caenorhabditis elegans
R Ved, S Saha, B Westlund, C Perier, L Burnam, A Sluder, M Hoener, ...
Journal of Biological Chemistry 280 (52), 42655-42668, 2005
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic-and antidepressant-like activity, improve cognition and control body weight
FG Revel, JL Moreau, B Pouzet, R Mory, A Bradaia, D Buchy, V Metzler, ...
Molecular psychiatry 18 (5), 543-556, 2013
The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system
A Bradaia, G Trube, H Stalder, RD Norcross, L Ozmen, JG Wettstein, ...
Proceedings of the National Academy of Sciences 106 (47), 20081-20086, 2009
Caenorhabditis elegans MPP+ Model of Parkinson’s Disease for High-Throughput Drug Screenings
E Braungart, M Gerlach, P Riederer, R Baumeister, MC Hoener
Neurodegenerative Diseases 1 (4-5), 175-183, 2004
Monoamine transporter and receptor interaction profiles of a new series of designer cathinones
LD Simmler, A Rickli, MC Hoener, ME Liechti
Neuropharmacology 79, 152-160, 2014
Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones
A Rickli, MC Hoener, ME Liechti
European Neuropsychopharmacology 25 (3), 365-376, 2015
Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges
MD Berry, RR Gainetdinov, MC Hoener, M Shahid
Pharmacology & therapeutics 180, 161-180, 2017
The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans
CM Hysek, LD Simmler, M Ineichen, E Grouzmann, MC Hoener, ...
Clinical pharmacology & therapeutics 90 (2), 246-255, 2011
Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2, 5-dimethoxy-substituted phenethylamines (2C drugs)
A Rickli, D Luethi, J Reinisch, D Buchy, MC Hoener, ME Liechti
Neuropharmacology 99, 546-553, 2015
Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out rats
D Leo, I Sukhanov, F Zoratto, P Illiano, L Caffino, F Sanna, G Messa, ...
Journal of Neuroscience 38 (8), 1959-1972, 2018
Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
CM Hysek, LD Simmler, VG Nicola, N Vischer, M Donzelli, S Krähenbühl, ...
PloS one 7 (5), e36476, 2012
Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics
FG Revel, JL Moreau, RR Gainetdinov, A Ferragud, ...
Biological psychiatry 72 (11), 934-942, 2012
Are there differences between the secretion characteristics of NGF and BDNF? Implications for the modulatory role of neurotrophins in activity‐dependent neuronal plasticity
O Griesbeck, M Canossa, G Campana, A Gärtner, MC Hoener, H Nawa, ...
Microscopy research and technique 45 (4‐5), 262-275, 1999
The system can't perform the operation now. Try again later.
Articles 1–20